Sanara MedTech reports Q2 EPS (23c) vs (41c) last year

Reports Q2 revenue $25.83M vs $20.16M last year. “We are pleased to deliver impressive net revenue performance in our Sanara Surgical segment, with 28% growth year-over-year in the second quarter of 2025, fueled by sales of CellerateRX Surgical, BIASURGE, and our portfolio of bone fusion products,” stated Ron Nixon, Sanara’s Executive Chairman and CEO. “This performance was made possible by the Sanara Surgical team’s focused execution on our commercial strategy: to continue expanding our network of distributor partners, adding new healthcare facilities to our customer base, and penetrating the existing facilities we serve.”